Oncogenic Viruses Volume 1
Fundamentals of Oncoviruses
- 1st Edition - September 14, 2022
- Imprint: Academic Press
- Editor: Moulay Mustapha Ennaji
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 1 5 2 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 1 3 - 4
Oncogenic Viruses: Fundamentals of Oncoviruses provides an overview of the history of human oncoviruses, how to discover and define an oncovirus, how viruses cause cancer in genera… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOncogenic Viruses: Fundamentals of Oncoviruses provides an overview of the history of human oncoviruses, how to discover and define an oncovirus, how viruses cause cancer in general, their oncogenic mechanisms and epidemiology, and the cancer biology of oncoviruses. The book is organized into five main parts that include history and discovery of virus-tumor complications, taxonomy and classification of oncoviruses, oncoviruses around the world, including epidemiology statistics and current methods. Finally, the book looks at the molecular epidemiology of DNA and RNA viruses and their role in the pathogenesis of human cancers.
- Provides an overview of the history, discovery, taxonomy and biology of oncoviruses
- Offers the fundamentals of viral implications in human tumors
- Covers the molecular epidemiology and oncologic implications and associations of DNA and RNA oncoviruses
Experts in the role of oncoviruses in tumorgenesis mechanisms; specialized researchers in viruses and human tumors; researchers in the molecular biology of cancer; researchers of fundamental virology studies; lecturers of virology, cancer in medicine, and microbiology
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- About the editor
- Preface
- Acknowledgments
- Chapter 1. General introduction oncogenic viruses: recent knowledge
- Abstract
- References
- Chapter 2. Hepatocellular carcinoma associated with hepatitis B virus and environmental factors
- Abstract
- 2.1 Introduction
- 2.2 Hepatocellular carcinoma
- 2.3 Anatomopathological characteristics
- 2.4 Nature and history of liver carcinogenesis
- 2.5 Molecular mechanism of hepatocarcinogenesis
- 2.6 Hepatitis B virus
- 2.7 Virological data
- 2.8 Natural history of hepatitis B virus infection
- 2.9 Antiviral treatment for hepatitis B
- 2.10 Hepatocellular carcinoma associated with hepatitis B virus
- 2.11 The link between hepatitis B virus and hepatic tumorigenesis
- 2.12 Molecular mechanisms of hepatocarcinogenesis induced by hepatitis B virus
- 2.13 Hepatocellular carcinoma associated with environmental factors
- 2.14 Metabolic and environmental risk factors
- 2.15 Nutritional risk factors for hepatocellular carcinoma
- 2.16 Prevention of risk factors
- 2.17 Synergy between hepatitis B virus and environmental factors in the etiology of hepatocellular carcinoma
- 2.18 Conclusion
- Acknowledgments
- References
- Chapter 3. General principals and mechanisms of viral oncogenic and associated cancers (cytomegalovirus, papillomaviruses, and RNA oncogenic virus)
- Abstract
- 3.1 Introduction
- 3.2 General information on oncogenic viruses:cytomegalovirus, papillomaviruses, and RNA oncogenic virus
- 3.3 Conclusion
- Acknowledgments
- References
- Chapter 4. Infection of HPV and MMTV oncovirus in breast cancer tissues in women
- Abstract
- 4.1 Introduction
- 4.2 Infection with human papillomavirus
- 4.3 Mouse mammary tumor virus infection
- 4.4 Discussion
- 4.5 Conclusion
- References
- Further reading
- Chapter 5. MicroRNAs associated with Helicobacter pylori and Epstein-Barr virus infections in gastric cancer
- Abstract
- 5.1 Introduction
- 5.2 Discovery and origin of microRNAs
- 5.3 Biogenesis of microRNAs
- 5.4 MicroRNAs in gastric cancer
- 5.5 Conclusion
- References
- Chapter 6. Breast cancer: epidemiology and viral ethology associated with human papillomavirus and mouse mammary tumor virus
- Abstract
- 6.1 Introduction
- 6.2 Breast cancer epidemiology
- 6.3 Risk factors for breast cancer
- 6.4 Human papillomaviruses and mouse mammary tumor virus in breast cancer
- 6.5 Conclusion
- References
- Chapter 7. Human papillomavirus infections and cervical cancer
- Abstract
- 7.1 Virology of human papillomavirus
- 7.2 Molecular architecture of human papillomavirus and features of viral pro-oncogenes and oncoproteins
- 7.3 Infection cell cycle and replication
- 7.4 Transmission mode and risk factors
- 7.5 Pathophysiology, evolution, and natural history of human papillomavirus infection
- 7.6 Cervical cancer: a preventable disease
- References
- Chapter 8. Covid-19 and cancer: impact on diagnosis, care and therapy
- Abstract
- 8.1 Introduction
- 8.2 Coronavirus disease
- 8.3 Factors affecting the pathogenesis of the virus
- 8.4 The impact of the COVID-19 pandemic on cancer care
- 8.5 The different types of anti-SARS-CoV-2 vaccine
- 8.6 SARS-CoV-2 vaccines in cancer patients
- 8.7 Conclusion
- Acknowledgments
- References
- Chapter 9. The role of DNA oncoviruses and its association with human cancer
- Abstract
- 9.1 Introduction
- 9.2 History, discovery, and types
- 9.3 Epidemiology
- 9.4 Viral proteins involved
- 9.5 General mechanism by which oncovirus induces cancer in DNA
- 9.6 Mechanism of action for each oncoviruses
- 9.7 Genome and structure of viruses
- 9.8 Cancers associated with DNA oncoviruses
- 9.9 Therapeutic options for DNA oncoviruses
- 9.10 Conclusion
- Acknowledgment
- References
- Chapter 10. RNA oncoviruses and their association with cancer implications
- Abstract
- 10.1 Introduction
- 10.2 Oncoviruses and their variants
- 10.3 Timeline of oncoviruses
- 10.4 Endogenous and exogenous retroviruses
- 10.5 Viral carcinogenesis
- 10.6 Reverse transcription and recognition of proto-oncogenes
- 10.7 Human T cell lymphotropic virus 1
- 10.8 Hepatitis C virus
- 10.9 Human immunodeficiency virus
- 10.10 Conclusion
- Abbreviation
- Acknowledgment
- References
- Chapter 11. Evolution of viruses: tumor complications
- Abstract
- 11.1 Introduction
- 11.2 Oncovirus and its prevalence
- 11.3 Epidemiology
- 11.4 Discovery of oncovirus and its timeline
- 11.5 Mechanism of oncovirus
- 11.6 Classification of oncoviruses
- 11.7 Genes associated with oncogenes and virus tumor complications
- 11.8 Causes and prevention
- 11.9 Therapies and treatment
- 11.10 Conclusion
- Acknowledgment
- References
- Chapter 12. HPV oncovirus: molecular biology and mechanism of action
- Abstract
- 12.1 Introduction
- 12.2 Recent progress
- 12.3 Discussion
- References
- Chapter 13. Oncogenic viruses and mechanism of oncogenesis: study of oncogenic characteristics of HTLV-1 and HHV-8 viruses
- Abstract
- 13.1 Introduction
- 13.2 Molecular aspects of human herpesvirus 8 and associated tumors
- 13.3 Molecular aspects of human T-lymphotropic virus type 1 and associated tumors
- 13.4 Conclusion
- References
- Chapter 14. Hepatitis C virus and hepatocellular carcinoma
- Abstract
- 14.1 Introduction
- 14.2 The drug target of hepatitis C virus
- 14.3 Progression from hepatitis C virus to hepatocellular carcinoma
- 14.4 Hepatocellular carcinoma
- 14.5 Drugs and drug targets in hepatocellular carcinoma
- 14.6 Diagnosis of hepatitis C virus
- 14.7 Tests for liver damage
- 14.8 Conclusion
- References
- Chapter 15. Prostate cancer and viral infections: epidemiological and clinical indications
- Abstract
- 15.1 Introduction
- 15.2 Prostate cancer: clinical aspects
- 15.3 Viral Infections as a risk factor for prostate cancer
- References
- Chapter 16. Oncogenic human virus associated with prostate cancer: molecular epidemiology of Human Papillomavirus and Epstein-Barr virus
- Abstract
- 16.1 Introduction
- 16.2 Conclusion
- References
- Chapter 17. Epidemiology of gynecological and mammary cancers in Africa: viral etiology and risk factors
- Abstract
- 17.1 Introduction
- 17.2 Generalities about cancer
- 17.3 Epidemiology of gynecomammary cancers in Africa
- 17.4 Overview of the molecular oncogenesis of gynecomammary cancer
- 17.5 Oncoviruses associated with gynecomammary cancer
- Acknowledgments
- References
- Chapter 18. Involvement of BK polyomavirus in genitourinary cancers
- Abstract
- 18.1 Introduction
- 18.2 The Polyomaviridae family
- 18.3 BK polyomavirus
- 18.4 Involvement of BK in genitourinary cancer
- 18.5 The kidney
- 18.6 Conclusion
- Acknowledgments
- References
- Chapter 19. Kidney cancer associated with Epstein-Barr virus
- Abstract
- 19.1 Introduction
- 19.2 Epstein-Barr virus
- 19.3 The association between kidney cancer and Epstein-Barr virus
- 19.4 Conclusion
- Acknowledgments
- References
- Further reading
- Chapter 20. The involvement of human papillomavirus in breast cancer in general and the different prognostic biomarkers in triple-negative breast cancer
- Abstract
- 20.1 Introduction
- 20.2 Anatomy of the mammary gland
- 20.3 Epidemiology
- 20.4 Human papillomavirus
- 20.5 Triple-negative breast cancer
- 20.6 Conclusion
- Acknowledgments
- References
- Chapter 21. Hypermethylation of tumor suppressor genes associated with Helicobacter pylori and Epstein–Barr virus infections in gastric cancer
- Abstract
- 21.1 Introduction
- 21.2 DNA methylation in gastric carcinogenesis
- 21.3 Helicobacter pylori and Epstein–Barr virus inducing aberrant methylation in the promoter of tumor suppressor genes
- 21.4 Helicobacter pylori coinfection with Epstein–Barr virus inducing aberrant methylation
- 21.5 Conclusion
- References
- Chapter 22. Etiology of human papillomavirus in cervical cancer and infection mechanism
- Abstract
- 22.1 Introduction
- 22.2 Human papillomavirus cervical cancer risk factors
- 22.3 Viral etiology of cervical cancer
- 22.4 Biology of papillomavirus
- 22.5 Interaction between E6 and p53 in the cancer pathway
- 22.6 Consequences of the E6 and p53 interaction
- 22.7 Interaction between E7 and pRb in the cancer pathway
- 22.8 Assessment of the joint action of oncoproteins E6 and E7
- 22.9 Vaccination is a way to fight against cervical cancer
- 22.10 Conclusion
- References
- Chapter 23. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
- Abstract
- 23.1 Introduction
- 23.2 Protein P53
- 23.3 Cell cycle arrest
- 23.4 Protein P21
- 23.5 Adenovirus
- 23.6 In vivo gene therapy with P53 or P21 adenovirus for prostate cancer
- 23.7 Conclusion
- References
- Index
- Edition: 1
- Published: September 14, 2022
- No. of pages (Paperback): 458
- No. of pages (eBook): 458
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128241523
- eBook ISBN: 9780323859134
ME
Moulay Mustapha Ennaji
Dr. Moulay Mustapha Ennaji, Professor in Virology and Oncology at the University of Casablanca and Director of the Quality and Medical Biotechnologies Team at Laboratory of Virology Microbiology, Hassan II University Mohammedia of Casablanca, Morocco He is currently a Professor in Virology and Oncology at the University of Casablanca, and since 2010, he has been the Director of the Quality and Medical Biotechnologies Team at the Laboratory of Virology Microbiology, Quality, Biotechnologies. He received a MSc in 1986 and a PhD in virology in 1993 from Armand Frappier Institute, University of Quebec (Canada). He has published dozens of journals articles and is an editorial board member of the journal, Infectious Agents and Cancer. Throughout his career, Dr. Ennaji has been rewarded several awards. At present, he is the vice president of the three Moroccan societies of Biosafety, Cancer, and Microbiology.
Affiliations and expertise
Professor, Virology and Oncology, University of Casablanca, Morocco; Director, Quality and Medical Biotechnologies Team, Laboratory of Virology Microbiology, Quality, Biotechnologies/Eco-Toxicology and Biodiversity; Faculty, Sciences and Techniques, Hassan II University Mohammedia of Casablanca, MoroccoRead Oncogenic Viruses Volume 1 on ScienceDirect